Characterizing highly benefited patients in randomized clinical trials

DOI10.1515/IJB-2016-0045MaRDI QIDQ6636136zbMATH OpenFDO

Authors Vivek Charu, Paul B. Rosenberg, Lon Schneider, Lea T. Drye, Lisa Rein, David Shade, Constantine G. Lyketsos, Constantine E. Frangakis

Publication date 12 November 2024

Published in The International Journal of Biostatistics (Search for Journal in Brave)

zbMATH Keywords

RCTAlzheimer's diseaseheterogeneity in treatment effectshigh benefit

Mathematics Subject Classification ID

Applications of statistics to biology and medical sciences; meta analysis (62P10)

Cites work

• A robust method for estimating optimal treatment regimes
• Analysis of randomized comparative clinical trial data for personalized treatment selections
• Bayesian inference for causal effects: The role of randomization
• Estimating individualized treatment rules using outcome weighted learning
• Structural nested models and G-estimation: the partially realized promise
• Targeted maximum likelihood learning
• The central role of the propensity score in observational studies for causal effects

This page was built for publication: Characterizing highly benefited patients in randomized clinical trials

Report a bug (only for logged in users!)Click here to report a bug for this page (MaRDI item Q6636136)